New immunotherapy combo aims to stop head and neck cancer return
Disease control
Not yet recruiting
This phase II trial tests the immunotherapy drug sintilimab combined with radiotherapy in patients with resectable locally advanced head and neck cancer. Participants receive sintilimab before surgery, then again after surgery along with radiation. The study aims to see if this a…
Phase: PHASE2 • Sponsor: chen chao Professor • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC